AtriCure (NASDAQ:ATRC) Given Market Outperform Rating at JMP Securities

JMP Securities restated their market outperform rating on shares of AtriCure (NASDAQ:ATRC – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has a $60.00 price objective on the medical device company’s stock. A number of other equities research analysts have also issued reports on the company. JPMorgan Chase […]

Leave a Reply

Your email address will not be published.

Previous post Roku (NASDAQ:ROKU) Shares Gap Down on Analyst Downgrade
Next post Wedbush Reiterates “Outperform” Rating for AnaptysBio (NASDAQ:ANAB)